Immunotherapy is increasingly being used to treat advanced bladder cancer (BLCA), particularly through the use of PD-L1 inhibitors, which suppress immune evasion by blocking the interaction between PD-1 and PD-L1 (67). Here, PDCD1 is linked to bladder transitional cell carcinoma.